Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example백신 개발에 "생리학적 재정규화를 위한 시스템 치료" 접근 방식을 사용합니다. 코로나19를 예로 들어Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] 변종, [키워드] adaptive immune system approach current example induce infectious agent mimicry Mutation physiological Prevent Recombination replicate respiratory tract respiratory tracts sera Spread the disease therapeutic Vaccine Vaccine development variant virions virulent [DOI] 10.1080/21645515.2022.2043105 PMC 바로가기 [Article Type] Article
Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021)Article Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval age anti-Nucleocapsid IgG antibodies antibody calculated Care circulating CIs conducted COVID-19 detect domains enzyme-linked immunosorbent enzyme-linked immunosorbent assay Gender groups Health Hypothesis IgG IgG antibody Immunoglobulin immunosorbent Italy multiplex nucleocapsid Piedmont positive test result prevalence rate proportion Receptor binding domain Result S1 and S2 S1 domain Sample SARS-CoV-2 SARS-CoV-2 antibody semiquantitative method sera Seroprevalence Serosurvey Support tested the spike protein Transmission dynamics virus [DOI] 10.1016/j.ijid.2022.09.017 PMC 바로가기
Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 OmicronArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Against B.1.1.529 Beta Breakthrough infection coronavirus coronavirus 2 Delta Delta infection humoral immune response Infection neutralization neutralize Neutralizing activity neutralizing antibody omicron potent respiratory SARS-CoV-2 sera serum significant increase vaccination Vaccine variant variants WA1 Wuhan-Hu-1 [DOI] 10.1093/infdis/jiac149 PMC 바로가기
Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assayArticle Published on 2022-11-012022-11-15 Journal: Diagnostic microbiology and infectious disease [Category] SARS, 진단, 치료기술, [키워드] Abbott anti-spike antibodies anti-spike antibody antibody Antibody test Antibody titer appear approved Architect assist benefit CMIA correlated strongly COVID-19 detect effective feasible female IgM/IgG immune response Immune status immunoassay individual IQR Lateral lateral flow lateral flow assay log-linear regression median age Microparticle monoclonal antibody monoclonal antibody therapy monoclonal antibody treatment natural infection participant Patient Prophylaxis SARS-CoV-2 SARS-CoV-2 IgG sera seronegative patient Severe COVID-19 Infection tested therapy Treatment undergo vaccination [DOI] 10.1016/j.diagmicrobio.2022.115788 PMC 바로가기
Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021Article Published on 2022-11-012022-11-15 Journal: Influenza and Other Respiratory Viruses [Category] COVID19(2023년), SARS, 진단, [키워드] absence age Anti-nucleocapsid antibodies antibody automatically children collected conducted confirmed COVID-19 case contributed COVID-19 COVID-19 case COVID-19 pandemic COVID-19 vaccination CrI cross-sectional cumulative estimate Estimated flow cytometric IgG antibody individual Infection Laboratory National Norway nucleocapsid nucleocapsid protein Prevalence RBD Receptor binding domain registry data residual SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 seroprevalence sera seropositive sample Seroprevalence the spike protein vaccination were measured women [DOI] 10.1111/irv.13024 PMC 바로가기
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathiesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 진단, [키워드] Administered administration age Alter analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies COVID-19 COVID-19 vaccination COVID-19 vaccine decrease dose enzyme-linked immunosorbent female healthy subjects IgA IgA titer IgG IgG titer IgM immune immunoassay Immunoglobulin impair indicate Interaction intravenous Intravenous immunoglobulin IVIG Microparticle mRNA vaccine observation Patient positive Prevalence reduce remained sera serological response serum serum titer significantly subsequent the antibody response therapeutic vaccination Vaccine vaccine dose vaccine interaction. [DOI] 10.1111/ene.15508 PMC 바로가기
Distinct Immune Phenotypes and Cytokine Profiles in Children with Differing Severity of COVID-19Article Published on 2022-11-012022-11-15 Journal: The Pediatric Infectious Disease Journal [Category] SARS, 진단, 치료기술, [키워드] Absolute lymphocyte count activated acute phase acute respiratory syndrome Anti-inflammatory Antibody Response CD3 CD4 CD8 Cell children children with COVID-19 Clinical outcome clinical presentation coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patients cytokine profile decrease dependent on disease severity distress effector memory exhibited groups help HLADR IL-1ra IL-1β immune mechanism Immune phenotype Immune profile increase in Infection Inflammatory Laboratory parameters Mild MIS-C no difference not significantly different Patient pediatric profile prospective cohort study RANTES SARS-CoV-2 IgG SARS-CoV2 sera severe disease severity syndrome T cell T cells tumor necrosis factor-α was performed with COVID-19 [DOI] 10.1097/INF.0000000000003669 PMC 바로가기
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] A570D A701V addition Affect affected antibodies antigenicity B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.617.2 BALB/c mice binding circulating cross-neutralization activity D1118H decrease Del Delta determine DNA vaccine Effects Efficiency elicited humoral immune response immune evasion immunized immunogen in vitro investigated K417N L18F Lineage Mutation NAbs Naturally neutralization Neutralizing Neutralizing antibodies neutralizing antibody NTD omicron opposite overcome P681H Pseudotyped viruses reduced S982A SARS-CoV-2 SARS-CoV-2 variant sera significantly increased single mutation single mutations spike mutation T cell T cell responses T-cell Response T716I tested the RBD Transmissibility unlikely Vaccine vaccine immunogenicity variants of concern viral entry viral infectivity VoC VOCs was determined weakened [DOI] 10.1038/s41423-022-00924-8 PMC 바로가기
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesArticle Published on 2022-10-292022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Antibody titer CCP collected convalescent plasma COVID-19 Donor dose effective geometric geometric mean titer Immune escape Immunocompromised implication Infection lesson monoclonal antibodies monoclonal antibody mRNA vaccine neutralization neutralize Neutralizing Neutralizing antibody titer omicron Outpatient pandemic plasma plasma activity provide recipients reduction representing SARS-CoV-2 variant sera subject therapeutic Therapies uninfected vaccinee variant variants of concern [DOI] 10.1038/s41467-022-33864-y PMC 바로가기
Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New JerseyArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료기술, [키워드] acute respiratory syndrome antibody antibody resistance attack rate B.1.351 B.1.526 Care caused characteristic Clinical use collected Community Complete coronavirus COVID-19 Critical E484K mutation Evidence Examining exhibit exhibited hcp Health highlight individual infected individuals Infection Inpatient Lineage loss of activity monoclonal antibody Mutation N-terminal domain neutralization capacity Neutralizing antibody response neutralizing capacity New nosocomial NTD outbreak P.1 Patient plasma positive professional professionals proportion pseudovirus psychiatric facility Receptor binding domain reported reverse transcription robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Spike protein Symptom symptomatic COVID-19 disease tested the SARS-CoV-2 the United State treat vaccinated individual vaccinated individuals vaccination Vaccine variant variants of concern VOCs wild type [DOI] 10.1128/mbio.02141-22 PMC 바로가기